Teladoc Health (NYSE:TDOC) Stock Jumps 8.1% – Time to Buy?

Teladoc Health, Inc. (NYSE:TDOC)’s stock price traded up 8.1% during trading on Tuesday. The stock traded as high as $6.18 and last traded at $6.1950. 1,880,053 shares were traded during trading, a decline of 63% from the average session volume of 5,040,161 shares. The stock had previously closed at $5.73.

Wall Street Analysts Forecast Growth

TDOC has been the topic of several analyst reports. Bank of America upped their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Citigroup decreased their price target on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Finally, Canaccord Genuity Group dropped their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Teladoc Health has an average rating of “Hold” and a consensus target price of $7.54.

Teladoc Health Trading Up 9.0%

The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -6.31 and a beta of 2.14. The firm’s 50 day moving average price is $6.19 and its two-hundred day moving average price is $6.89.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. During the same period last year, the business posted ($0.19) EPS. Teladoc Health’s revenue was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, equities research analysts predict that Teladoc Health, Inc. will post -0.92 EPS for the current year.

Insider Activity

In other news, CEO Charles III sold 17,805 shares of Teladoc Health stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the transaction, the chief executive officer directly owned 465,535 shares in the company, valued at approximately $2,839,763.50. The trade was a 3.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teladoc Health

A number of large investors have recently added to or reduced their stakes in the business. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Teladoc Health during the 2nd quarter worth $1,447,000. Monaco Asset Management SAM acquired a new stake in shares of Teladoc Health during the second quarter worth $26,864,000. ABS Investment Management LLC bought a new stake in shares of Teladoc Health in the second quarter valued at about $1,513,154. ABS Direct Equity Fund LLC bought a new stake in shares of Teladoc Health in the second quarter valued at about $1,513,000. Finally, Legal & General Group Plc acquired a new position in shares of Teladoc Health in the second quarter valued at about $1,358,000. Institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc (NYSE: TDOC) provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.

The company’s offerings include Teladoc’s telehealth services, BetterHelp’s online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.